F
Fabrice Barlesi
Researcher at Aix-Marseille University
Publications - 666
Citations - 36214
Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.
Papers
More filters
Journal ArticleDOI
Postgraduate oncology educational shifts during the COVID-19 pandemic: results of faculty and medical student surveys
Antoine Moya-Plana,Lambros Tselikas,Olivier Lambotte,Stéphane Temam,T. de Baere,Eric Deutsch,Fabrice Barlesi,Paige Blanchard,A. Levy +8 more
TL;DR: In this article , the authors conducted two surveys from June 2021 to October 2021 to students and faculty teachers (250 and 80 responses, respectively) who registered at Gustave Roussy School of Cancer Sciences (Université Paris-Saclay) during three consecutive university years (October 2018 toOctober 2021), where a major shift to e-learning was associated with COVID-19 pandemic.
Journal Article
Nodules léiomyomateux multiples du poumon : léiomyome métastatique bénin ?
TL;DR: In this article, the authors reviewed literature to know if the controversial question of benign metastasising leiomyomas could be resolved, and discussed the therapeutic possibilities of this pathology.
Journal ArticleDOI
EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients
Adrien Dixmier,Didier Debieuvre,C. Raspaud,Jean-Bernard Auliac,N. Benoit,P. Bombaron,Bernard Asselain,A. Dumont,P. Lamoureux,N. Goyard,Denis Moro-Sibilot,Maurice Pérol,Fabrice Barlesi,C. Audigier Valette +13 more
Journal ArticleDOI
[Anti-angiogenic factors in thoracic oncology: successes, failures and prospects]
TL;DR: A review of the literature on the effectiveness of anti-angiogenic treatments in non-small cell lung cancer (NSCLC), small cell lung Cancer (SCLC) and malignant pleural mesothelioma (MM) is presented in this article.
Journal ArticleDOI
[Use of genome-wide testing in oncology: French expert opinion based on the Delphi methodology].
TL;DR: In this article , a national consensus approach based on a modified Delphi methodology was set up to provide expert opinion on the use of genome-wide testing in clinical practice in France, and four groups of experts -4 each representing the following topics of interest -were defined: non-small cell lung cancer (NSCLC), breast cancer, melanoma, and cancer of unknown primary (CUP).